Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | COMT | P21964 | 1/20 | 0.37 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15206614 | 0.98 | SMN1; SMN2 (0.42) | NPSR1SMN1; SMN2MAPTHTTCOMT | |
| SCHEMBL58060 | 0.84 | PTGS1 (0.42) | NPSR1MAPTHTTPOLBMAPK1 | |
| SCHEMBL7014795 | 0.84 | NPSR1 (0.46) | NPSR1SMN1; SMN2MAPTHTTCOMT | |
| SCHEMBL17619238 | 0.83 | MAPT (0.33) | SMN1; SMN2MAPTPOLBMAPK1ALDH1A1 | |
| SCHEMBL17603797 | 0.83 | SMN1; SMN2 (0.41) | NPSR1SMN1; SMN2MAPTHTTCOMT | |
| SCHEMBL4599296 | 0.81 | TDP1 (0.35) | MAPTPOLBALDH1A1 | |
| SCHEMBL117827 | 0.78 | NPSR1 (0.54) | NPSR1SMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL29502585 | 0.78 | NPSR1 (0.54) | NPSR1SMN1; SMN2MAPTALDH1A1KDM4E | |
| SCHEMBL2343678 | 0.78 | MAPT (0.44) | NPSR1SMN1; SMN2MAPTHTTCOMT | |
| SCHEMBL20223115 | 0.76 | HTT (0.43) | SMN1; SMN2MAPTHTTPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116143806-A | Nitrogen-containing heterocyclic compound, preparation method and application | 上海凌达生物医药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-112830928-A | Pyrimido-cyclic derivative and application thereof in medicine | 四川海思科制药有限公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2020-02-27 | — | — | US | disclosed |
| EP-3519402-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-10280172-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-06-07 | — | — | US | disclosed |
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-06-07 | — | — | US | disclosed |
| WO-2018064510-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2018-04-05 | — | — | WO | disclosed |
| EP-2958918-B1 | DIHYDROPTERIDINONES II | BOEHRINGER INGELHEIM INT (DE) | 2016-12-07 | — | — | EP | disclosed |
| EP-1812424-A4 | KINASE INHIBITORS | MIIKANA THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-02-12 | — | — | US | disclosed |
| US-20080200485-A1 | Kinase Inhibitors | MIIKANA THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080200485-A1 | Kinase Inhibitors | MIIKANA THERAPEUTICS, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051494-A1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1812424-A2 | KINASE INHIBITORS | Miikana Therapeutics, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006055831-A2 | KINASE INHIBITORS | MIIKANA THERAPEUTICS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | NPSR1 4581/4885SMN1; SMN2 1674/4885MAPT 251/4885 |
| US-10723738-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | NPSR1 4558/4885SMN1; SMN2 1774/4885MAPT 258/4885 |
| US-20200062761-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | NPSR1 4558/4885SMN1; SMN2 1774/4885MAPT 258/4885 |
| US-20080200485-A1 | Kinase Inhibitors | AURKC, AURKA, AURKB | NPSR1 4783/4885SMN1; SMN2 3802/4885MAPT 1148/4885 |
| US-10280172-B2 | Inhibitors of KRAS G12C mutant proteins | KRAS, NRAS, HRAS | NPSR1 4581/4885SMN1; SMN2 1674/4885MAPT 251/4885 |
| US-20090042890-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, CHEK2, SRC | NPSR1 3965/4885SMN1; SMN2 3850/4885MAPT 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.